Y Xiong1, Y Jia, H Wang, G Liu, H Ren, Z Zhuo, D Zhang. 1. Transgenic Engineering Lab, Inrections Disease Centre of PLA, 458th Hospital of PLA, Guangzhou 510602, China.
Abstract
OBJECTIVE: To establish hepatitis B virus (HBV) transgenic mice models and to investigate if the model can be used for the evaluation of anti-HBV drugs. METHODS: HBV transgenic mice models were produced by microinjection to analyze the integration, expression of HBV in the transgenic mice by nested PCR, southern blot, immunohistochemistry, and ELISA. Sixty mice whose HBV DNA, HBsAg were positive were divided into 6 groups randomly, in which 3 groups were given drugs: lamivudine administrated by perfusion of stomach tube (100mg x kg(-1) x day(-1) for 21 days); thymosine administrated by abdomen injection (3mg x day(-1) for 90 days); and DNA vaccine of 100 microg by muscle injection. The other 3 groups were negative control. RESULTS: Lamivudine, thymosine and DNA vaccine made HBV DNA become negative in the serum of HBV transgenic mice. The negative ratio was highest in lamivudine treatment group. HBV DNA became positive again when lamivudine terminated. CONCLUSION: Limvudine, thymosine, and DNA vaccine can inhibit HBV replication. Transgenic mice might be used as the model for anti-HBV drug screening and evaluation.
OBJECTIVE: To establish hepatitis B virus (HBV) transgenic mice models and to investigate if the model can be used for the evaluation of anti-HBV drugs. METHODS:HBVtransgenic mice models were produced by microinjection to analyze the integration, expression of HBV in the transgenic mice by nested PCR, southern blot, immunohistochemistry, and ELISA. Sixty mice whose HBV DNA, HBsAg were positive were divided into 6 groups randomly, in which 3 groups were given drugs: lamivudine administrated by perfusion of stomach tube (100mg x kg(-1) x day(-1) for 21 days); thymosine administrated by abdomen injection (3mg x day(-1) for 90 days); and DNA vaccine of 100 microg by muscle injection. The other 3 groups were negative control. RESULTS:Lamivudine, thymosine and DNA vaccine made HBV DNA become negative in the serum of HBVtransgenic mice. The negative ratio was highest in lamivudine treatment group. HBV DNA became positive again when lamivudine terminated. CONCLUSION:Limvudine, thymosine, and DNA vaccine can inhibit HBV replication. Transgenic mice might be used as the model for anti-HBV drug screening and evaluation.
Authors: Jung Sun Yum; Byung Cheol Ahn; Hyun Jin Jo; Dong Yeon Kim; Ki Hyun Kim; Hyo Sun Kim; Young Chul Sung; Jaeseung Yoon; John Morrey; Hong Mo Moon Journal: Clin Vaccine Immunol Date: 2011-12-07